¼¼°èÀÇ Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º ½ÃÀå
Chronotherapy Services
»óǰÄÚµå : 1731993
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,082,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,248,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º ½ÃÀåÀº 2030³â±îÁö 10¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 8¾ï 3,260¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º ½ÃÀåÀº 2024-2030³â¿¡ CAGR 3.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 10¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Å©·Î³ëÅ×¶óÇÇ ½Ã½ºÅÛÀº CAGR 4.1%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 5,810¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Å©·Î³ëÅ×¶óÇÇ¾à ºÎ¹®Àº ºÐ¼® ±â°£ Áß CAGR 1.9%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 2,680¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º ½ÃÀåÀº 2024³â¿¡ 2¾ï 2,680¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 2¾ï 150¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 6.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.2%¿Í 2.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Å©·Î³ëÅ×¶óÇǰ¡ ½Ã°£ ÃÖÀûÈ­ Ä¡·á Àü·«À¸·Î ÀÓ»óÀû ¸ð¸àÅÒÀ» ¾ò°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Å©·Î³ëÅ×¶óÇÇ(»ýü¸®µë¿¡ ¸ÂÃá Àü·«Àû Ä¡·á ŸÀ̹Ö)´Â ¸ÂÃãÇü ÀÇ·áÀÇ ÆÐ·¯´ÙÀÓ º¯È­·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. »ýü½Ã°è°¡ È£¸£¸ó ºÐºñ, ´ë»ç, ¸é¿ª¹ÝÀÀ, ¼¼Æ÷Áõ½Ä µî ÁÖ¿ä »ý¸®±â´ÉÀ» Á¶ÀýÇϰí ÀÖ´Ù´Â °ÍÀº °úÇÐÀû Áõ°Å¿¡ ÀÇÇØ °è¼Ó ÀÔÁõµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ °íÇ÷¾Ð, õ½Ä, ¾Ï, ·ù¸¶Æ¼½º °üÀý¿°, Á¤½ÅÁúȯ µîÀÇ ¸¸¼ºÁúȯ¿¡¼­ ÀÌ·¯ÇÑ »ýü½Ã°è¿¡ ¸ÂÃß¾î Ä¡·áÁ¦¸¦ Åõ¿©ÇÏ¸é ¾àÈ¿¸¦ Å©°Ô °³¼±ÇÏ°í µ¶¼ºÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

Å©·Î³ë»ý¹°Çп¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁü¿¡ µû¶ó ÇコÄÉ¾î ½Ã½ºÅÛÀº ¾à¹° Åõ¿©, ¹æ»ç¼± Ä¡·á, Çൿ ÁßÀç, Áúº´ °ü¸® ÇÁ·ÎÅäÄÝ¿¡ Á¤È®ÇÑ ½Ã°£´ë¸¦ ÅëÇÕÇϱ⠽ÃÀÛÇß½À´Ï´Ù. Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º´Â ´Ü¼øÇÑ ½ºÄÉÁÙ¸µ¿¡ ±×Ä¡Áö ¾Ê°í, ¼øÈ¯ Áø´Ü, ¸ÂÃã Ä¡·á °èȹ, ¹ÙÀÌ¿À¸¶Ä¿ µ¥ÀÌÅÍ¿Í ¿þ¾î·¯ºí ±â¼úÀ» Ȱ¿ëÇÑ Å¸ÀÌ¹Ö ¾Ë°í¸®ÁòÀ» Æ÷ÇÔÇÕ´Ï´Ù. Á¤¹Ð Ä¡·á, °á°ú ±â¹Ý Ä¡·á, ȯÀÚ Áß½ÉÀÇ Ä¡·á ÃÖÀûÈ­¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½Å°ú ¿þ¾î·¯ºíÀº ¾î¶»°Ô Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½ºÀÇ È®Àå °¡´ÉÇÑ Á¦°øÀ» °¡´ÉÇÏ°Ô Çϴ°¡?

µðÁöÅÐ °Ç°­ Ç÷§Æû°ú »ýü ÃøÁ¤ ¿þ¾î·¯ºíÀº ½Ç½Ã°£ ÀÏÁֱ⠸®µë ¸ð´ÏÅ͸µ°ú ÀûÀÀÇü °³ÀÔ ½ºÄÉÁÙ¸µÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Å©·Î³ëÅ×¶óÇÇÀÇ ½Ç¿ëÈ­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¼ö¸é ¹× °¢¼º ÁÖ±â, ½É¹Ú¼ö, ü¿Â, ¸á¶óÅä´Ñ ºÐºñ¸¦ ÃßÀûÇÏ´Â Àåºñ´Â °³ÀÎ ¸ÂÃãÇü ÀÏÁÖ±â ÇÁ·ÎÆÄÀÏÀ» »ý¼ºÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÃÖÀûÀÇ ¾à¹° Åõ¿©·®, Çൿ Ä¡·áÀÇ Å¸À̹Ö, Ä¡·á ÀÏÁ¤À» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ÀÓ»óÀÇ¿¡°Ô º¸´Ù ¿ªµ¿ÀûÀÌ°í ±Ù°Å¿¡ ±â¹ÝÇÑ Ä¡·á Á¦°ø ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

ÀΰøÁö´É°ú ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº ÀÏÁֱ⠹ÙÀÌ¿À¸¶Ä¿¸¦ ºÐ¼®Çϰí Å©·Î³ëÀ¯Çü¿¡ µû¸¥ Ä¡·á ¹ÝÀÀÀ» ¿¹ÃøÇÏ´Â µ¥¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ °Ç°­ ¾Û, ½º¸¶Æ® ¾Ë¾à µð½ºÆæ¼­, ½Ã°£ µ¿±âÈ­ Åõ¾à ½Ã½ºÅÛÀº ƯÈ÷ ¿Ü·¡ ¹× ÀçÅÃÄ¡·á¿¡¼­ Å©·Î³ëÅ×¶óÇÇ ÇÁ·ÎÅäÄÝÀÇ ÀÚµ¿ Áؼö¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº Ä¡·á µ¶¼º ¹× Á¾¾ç ¹ÝÀÀÀÌ Åõ¿© ½Ã°£¿¡ µû¶ó Å©°Ô ´Þ¶óÁú ¼ö ÀÖÀ¸¸ç, Á¤È®ÇÑ Ä¡·á ½ºÄÉÁÙ¸µÀÌ ÀÓ»óÀû ¿ì¼±¼øÀ§°¡ µÇ´Â Á¾¾çÇÐ ºÐ¾ß¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º µµÀÔÀ» ÁÖµµÇϰí ÀÖ´Â ÀÓ»ó ºÐ¾ß´Â ¾îµðÀΰ¡?

Á¾¾çÇÐÀº Å©·Î³ëÅ×¶óÇÇ µµÀÔÀÇ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, ÀÓ»ó ¿¬±¸¿¡ µû¸£¸é È­Çпä¹ýÀÇ È¿°ú¿Í µ¶¼ºÀÌ ½Ã°£¿¡ µû¶ó º¯µ¿ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÁÖ±âÀû ½ºÄÉÁÙ¸µÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï¿¡¼­ ¿Á»ì¸®Çöóƾ, ½Ã½ºÇöóƾ, 5-Ç÷ç¿À·Î¶ó½Ç°ú °°Àº ¾à¹°ÀÇ ³»¾à¼º°ú Ä¡·á Áö¼ö¸¦ Çâ»ó½ÃÄ×½À´Ï´Ù. »ý¹°ÇÐÀûÀ¸·Î ÃÖÀûÀÇ Å¸Àֿ̹¡ ¹æ»ç¼± Ä¡·á¸¦ ÇÏ´Â Å©·Î³ë¹æ»ç¼±µµ Á¤»ó Á¶Á÷ º¸È£¿Í Á¾¾ç Á¶ÀýÀ» °­È­Çϱâ À§ÇÑ ¸ñÀûÀ¸·Î Á¾¾çÇÐ ÀÓ»ó¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù.

Ç÷¾ÐÀº ÀÏÁֱ⠸®µëÀ» µû¸£¸ç, °­¾ÐÁ¦ÀÇ ¾ß°£ Åõ¿©°¡ 24½Ã°£ Ç÷¾Ð Á¶Àý°ú ½ÉÇ÷°ü°è ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. Á¤½ÅÀÇÇп¡¼­´Â ±âºÐÀå¾Ö, ¾ç±Ø¼º Àå¾Ö, ¼ö¸éÀå¾Ö°¡ ±¤¼±¿ä¹ý, ¸á¶óÅä´Ñ ½Ã°£ Á¶Àý, ÀÏÁֱ⠸®µë¿¡ µû¸¥ ¾à¹°¿ä¹ýÀ¸·Î °ü¸®µÇ°í ÀÖ½À´Ï´Ù. ½Å°æÇÐ, È£Èí±âÇÐ, ³»ºÐºñÇп¡¼­µµ ¾à¹° ´ë»ç, È£¸£¸ó Á¶Àý, ¿°Áõ Á¶ÀýÀ» °³¼±Çϱâ À§ÇÑ ½Ã°£ ±â¹Ý ÁßÀç°¡ ¸ð»öµÇ°í ÀÖ½À´Ï´Ù.

ÀÇ·á ½Ã½ºÅÛ°ú ÁöºÒÀÚ´Â Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½ºÀÇ ÅëÇÕ°ú »óȯÀ» À§ÇØ ¾î¶»°Ô ³ë·ÂÇϰí Àִ°¡?

Å©·Î³ëÅ×¶óÇÇ´Â °úÇÐÀûÀ¸·Î °ËÁõµÇ¾úÁö¸¸, ±¸Á¶Àû, »óȯ ¹× ÀνĻóÀÇ ¹®Á¦·Î ÀÎÇØ ÁÖ·ù ÀÓ»ó Áø·á¿¡ ´ëÇÑ ÅëÇÕÀº ¾ÆÁ÷ ±ÕÀÏÇÏ°Ô ÀÌ·ç¾îÁöÁö ¾Ê°í ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ÀÇ·á ¼­ºñ½º Á¦°ø ¸ðµ¨Àº ¾ÆÁ÷ ¼øÈ¯ ±â¹Ý Ä¡·á ½ºÄÉÁÙ¸µ¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ±¸¼ºµÇÁö ¾Ê¾ÒÀ¸¸ç, ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¿öÅ©Ç÷δ Á¾Á¾ ½Ã°£¿¡ µû¶ó °³ÀÔÀ» Á¶Á¤ÇÒ ¼ö ÀÖ´Â À¯¿¬¼ºÀÌ ºÎÁ·ÇÕ´Ï´Ù. ¶ÇÇÑ ½Ã°£º° Ä¡·á Åõ¿©¿¡ ´ëÇÑ »óȯÀÌ Ç¥ÁØÈ­µÇ¾î ÀÖÁö ¾Ê¾Æ µµÀÔ¿¡ ´ëÇÑ Àμ¾Æ¼ºê°¡ Á¦ÇѵǾî ÀÖ½À´Ï´Ù.

±×·³¿¡µµ ºÒ±¸ÇÏ°í ÆÄÀÏ·µ ÇÁ·Î±×·¥À̳ª ´ëÇк´¿ø¿¡¼­´Â Å©·Î³ëÅ×¶óÇÇ ÇÁ·ÎÅäÄÝÀÇ ºñ¿ë È¿°ú¿Í ÀÓ»óÀû °¡Ä¡¸¦ ÀÔÁõÇϰí ÀÖ½À´Ï´Ù. À¯·´, ÀϺ», ¹Ì±¹ÀÇ ÀϺΠÀÇ·á±â°ü¿¡¼­´Â Å©·Î³ë¸Þµð½ÅŬ¸®´ÐÀ» ½Ã¹üÀûÀ¸·Î µµÀÔÇϰí, ÀüÀÚÀǹ«±â·Ï ½Ã½ºÅÛÀ̳ª Ä¡·á °¡À̵å¶óÀο¡ Å©·Î³ë¹ÙÀÌ¿À·ÎÁö ¿øÄ¢À» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ Ä¡·á ½Ã±â¸¦ ÃÖÀûÈ­ÇÏ¿© ºÎÀÛ¿ëÀ» ÁÙÀ̰í, º¹¾à ¼øÀÀµµ¸¦ °³¼±Çϸç, ÀÔ¿øÀ» ÇÇÇÒ ¼ö ÀÖ´Â ºÎ´ãÀÌ Å« ÁúȯÀÇ °æ¿ì, º¸Çè ÁöºÒÀÚ´Â ¼øÈ¯±â Áúȯ¿¡ ´ëÇÑ º¸Çè Àû¿ë ¸ðµ¨À» °ËÅäÇϱ⠽ÃÀÛÇß½À´Ï´Ù.

Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º°¡ ¼¼°è ½ÃÀå¿¡¼­ Á¤¹ÐÀÇ·áÀÇ ÁÖ·ù°¡ µÉ ¼ö Àִ°¡?

Å©·Î³ëÅ×¶óÇÇ´Â ½ÅüÀÇ ÀÚ¿¬Àû ¸®µëÀ» Ȱ¿ëÇÏ¿© Ä¡·á °á°ú¸¦ °³¼±ÇÒ ¼ö Àִ Ⱦ´ÜÀû Çõ½ÅÀ¸·Î Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ±×·¯³ª Å©·Î³ëÅ×¶óÇǰ¡ ÁÖ·ù°¡ µÇ±â À§Çؼ­´Â È®Àå °¡´ÉÇÑ Á¦°ø ¸ðµ¨ °³¹ß, ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ ±³À°, Áúº´ ¿µ¿ª¿¡ °ÉÄ£ ¸íÈ®ÇÑ ÀÓ»ó ÇÁ·ÎÅäÄÝÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ ÀÓ»óÀÇ¿Í ÀÌÇØ°ü°èÀڵ鿡°Ô Àü½ÅÀû ÀÌÁ¡À» ³³µæ½Ãų ¼ö Àִ źźÇÑ ½ÇÁ¦ ÀÓ»ó Áõ°Å, ÀÌÇØ°ü°èÀÚ ±³À°, °æÁ¦Àû °ËÁõÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÇコÄɾ °³ÀÎÈ­, È¿À²È­, ¿¹¹æÀÇÇÐÀ¸·Î ÀüȯµÇ´Â °¡¿îµ¥, Áß¿äÇÑ ¹®Á¦´Â ´ÙÀ½°ú °°½À´Ï´Ù. Å©·Î³ëÅ×¶óÇÇ ¼­ºñ½º°¡ ´Ù¾çÇÑ ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¿î¿µ, ±ÔÁ¦, Á¢±ÙÀÇ À庮À» ±Øº¹Çϰí, ½Ã°£Àû Àϰü¼ºÀ» À¯ÁöÇϸç, ȯÀÚ ¸ÂÃãÇü ÁßÀ縦 ´ë±Ô¸ð·Î Á¦°øÇϰí, ±¤¹üÀ§ÇÏ°Ô Ã¤ÅõǴ Á¤¹ÐÀÇ·á Åø·Î ¼º¼÷ÇÒ ¼ö Àִ°¡?

ºÎ¹®

Á¦Ç° À¯Çü(Å©·Î³ëÅ×¶óÇÇ ½Ã½ºÅÛ, Å©·Î³ëÅ×¶óÇǾà), Ä¡·á ¿µ¿ª(Á¾¾çÇÐ, ½Å°æÇÐ, ½ÉÇ÷°ü°è Áúȯ, È£Èí±â Áúȯ, ±âŸ Ä¡·á ¿µ¿ª), ÃÖÁ¾ »ç¿ë(º´¿ø¡¤Å¬¸®´Ð, ÀçÅà ÀÇ·á, ±âŸ ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 42»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Chronotherapy Services Market to Reach US$1.0 Billion by 2030

The global market for Chronotherapy Services estimated at US$832.6 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Chronotherapy Systems, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$658.1 Million by the end of the analysis period. Growth in the Chronotherapy Drugs segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$226.8 Million While China is Forecast to Grow at 6.3% CAGR

The Chronotherapy Services market in the U.S. is estimated at US$226.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$201.5 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Chronotherapy Services Market - Key Trends & Drivers Summarized

Why Is Chronotherapy Gaining Clinical Momentum as a Time-Optimized Therapeutic Strategy?

Chronotherapy-the strategic timing of medical treatment to align with the body's circadian rhythms-is emerging as a paradigm shift in personalized medicine. Scientific evidence continues to demonstrate that the body’s biological clock regulates key physiological functions such as hormone secretion, metabolism, immune response, and cell proliferation. Administering therapies in sync with these circadian cycles can significantly improve efficacy and reduce toxicity, particularly in chronic conditions like hypertension, asthma, cancer, rheumatoid arthritis, and psychiatric disorders.

As understanding of chronobiology deepens, healthcare systems are beginning to integrate time-of-day precision into drug administration, radiation therapy, behavioral interventions, and disease management protocols. Chronotherapy services extend beyond simple scheduling-they encompass circadian diagnostics, personalized treatment plans, and timing algorithms powered by biomarker data and wearable technology. This approach is becoming increasingly relevant amid growing demand for precision therapeutics, outcome-based care, and patient-centric treatment optimization.

How Are Technological Innovations and Wearables Enabling Scalable Delivery of Chronotherapy Services?

Digital health platforms and biometric wearables are playing a critical role in operationalizing chronotherapy by enabling real-time circadian rhythm monitoring and adaptive scheduling of interventions. Devices that track sleep-wake cycles, heart rate variability, body temperature, and melatonin secretion are being used to generate individualized circadian profiles. This data informs optimal dosing windows for medications, behavioral therapy timing, and scheduling of procedures, offering clinicians a more dynamic, evidence-based approach to care delivery.

Artificial intelligence and machine learning algorithms are also being employed to analyze circadian biomarkers and predict chronotype-based treatment responses. Mobile health apps, smart pill dispensers, and time-synchronized infusion systems are facilitating automated adherence to chronotherapy protocols, especially in ambulatory and home-care settings. These tools are particularly valuable in oncology, where treatment toxicity and tumor response can vary markedly by dosing time, making the precise scheduling of therapies a clinical priority.

Which Clinical Domains Are Leading the Adoption of Chronotherapy Services?

Oncology is at the forefront of chronotherapy adoption, with clinical studies showing time-of-day-dependent variability in chemotherapy efficacy and toxicity. Circadian-based scheduling is improving tolerability and therapeutic index for agents such as oxaliplatin, cisplatin, and 5-fluorouracil in colorectal, breast, and lung cancers. Chronoradiation-delivering radiotherapy at biologically optimal times-is also gaining traction in oncology clinics aiming to enhance normal tissue protection and tumor control.

Beyond cancer, chronotherapy is being applied in cardiovascular disease management, where blood pressure follows a circadian rhythm and nighttime dosing of antihypertensives has been shown to improve 24-hour control and cardiovascular outcomes. In psychiatric care, mood disorders, bipolar disorder, and sleep disturbances are increasingly managed through light therapy, timed melatonin, and circadian-aligned pharmacotherapy. Neurology, pulmonology, and endocrinology are also exploring time-based interventions to improve drug metabolism, hormone regulation, and inflammatory modulation.

How Are Healthcare Systems and Payers Approaching Integration and Reimbursement of Chronotherapy Services?

While chronotherapy is scientifically validated, its integration into mainstream clinical practice remains uneven due to structural, reimbursement, and awareness challenges. Most healthcare delivery models are not yet configured to accommodate circadian-based treatment scheduling, and provider workflows often lack the flexibility to tailor interventions by time. Moreover, reimbursement for time-specific therapeutic administration is not standardized, limiting incentives for adoption.

That said, pilot programs and academic medical centers are increasingly demonstrating the cost-effectiveness and clinical value of chronotherapy protocols. Health systems in Europe, Japan, and select U.S. centers are experimenting with chronomedicine clinics and integrating chronobiological principles into electronic health record systems and treatment guidelines. Payers are beginning to explore coverage models that support circadian-aligned care, particularly for high-burden conditions where optimized timing can reduce adverse events, improve medication adherence, and avoid hospitalizations.

Can Chronotherapy Services Evolve into a Mainstream Pillar of Precision Medicine Across Global Markets?

Chronotherapy holds significant promise as a cross-cutting innovation that can improve treatment outcomes by harnessing the body’s natural rhythms. However, its mainstreaming will depend on the development of scalable delivery models, provider training, and clear clinical protocols across disease areas. Broad acceptance will require robust real-world evidence, stakeholder education, and economic validation to convince clinicians and payers of its systemic benefits.

As healthcare pivots toward personalization, efficiency, and preventative care, the critical question becomes: Can chronotherapy services mature into a widely adopted precision medicine tool-delivering time-aligned, patient-specific interventions at scale while addressing operational, regulatory, and access barriers across diverse health systems?

SCOPE OF STUDY:

The report analyzes the Chronotherapy Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chronotherapy Systems, Chronotherapy Drugs); Therapeutic Area (Oncology, Neurology, Cardiovascular Diseases, Respiratory Diseases, Other Therapeutic Areas); End-Use (Hospitals & Clinics, Homecare Settings, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â